mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
about
Recent advances in hepatocellular carcinoma therapy.Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.MEIS-1 level in unresectable hepatocellular carcinoma can predict the post-treatment outcomes of radiofrequency ablation.
P2860
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
mRECIST response combined with ...... ated with TACE plus sorafenib.
@en
mRECIST response combined with ...... ated with TACE plus sorafenib.
@nl
type
label
mRECIST response combined with ...... ated with TACE plus sorafenib.
@en
mRECIST response combined with ...... ated with TACE plus sorafenib.
@nl
prefLabel
mRECIST response combined with ...... ated with TACE plus sorafenib.
@en
mRECIST response combined with ...... ated with TACE plus sorafenib.
@nl
P2093
P2860
P356
P1476
mRECIST response combined with ...... ated with TACE plus sorafenib.
@en
P2093
Daiming Fan
Dongdong Xia
Enxin Wang
Guohong Han
Hongwei Cai
Jielai Xia
P2860
P304
P356
10.1002/IJC.30451
P577
2016-09-28T00:00:00Z